[go: up one dir, main page]

AR035321A1 - Derivados de 2-arilimino-2,3-dihidrotiazoles, procedimiento para su preparacion, y uso de los mismos para preparar medicamentos y composiciones farmaceuticas - Google Patents

Derivados de 2-arilimino-2,3-dihidrotiazoles, procedimiento para su preparacion, y uso de los mismos para preparar medicamentos y composiciones farmaceuticas

Info

Publication number
AR035321A1
AR035321A1 ARP000103722A ARP000103722A AR035321A1 AR 035321 A1 AR035321 A1 AR 035321A1 AR P000103722 A ARP000103722 A AR P000103722A AR P000103722 A ARP000103722 A AR P000103722A AR 035321 A1 AR035321 A1 AR 035321A1
Authority
AR
Argentina
Prior art keywords
alkyl
radical
aryl
optionally substituted
cycloalkyl
Prior art date
Application number
ARP000103722A
Other languages
English (en)
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Publication of AR035321A1 publication Critical patent/AR035321A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)

Abstract

Derivados de 2-arilimino-2,3-dihidrotiazoles, procedimiento para su preparación, y uso de los mismos para preparar medicamentos y composiciones farmacéuticas, de la fórmula general (1) donde R1, R2, R3 y R4 toman los siguientes valores: R1 representa un amino(C2-7)alquilo, amino alquilaril alquilo, aminoalquil cicloalquil alquilo, (C1-15)alquilo, (C3-7)cicloalquilo, (C1-6)alquil(C3-6)cicloalquilo, (C3-6)cicloalquil alquilo, ciclo hexenil alquilo, alquenilo, alquinilo, un radical arilo carbocíclico que contiene por lo menos dos anillos de los cuales por lo menos uno no es aromático, un radical aralquilo carbocíclico o heterocíclico opcionalmente sustituido en el grupo arilo, un radical bis-arialquilo, alcoxialquilo, furanil alquilo, tetrahidro furanil alquilo, dialquil amino alquilo, N-acetamido alquilo, ciano alquilo, alquiltio alquilo, arilhidroxi alquilo, aralcoxi alquilo, morfolino alquilo, pirrolidino alquilo, piperidino alquilo, N-alquil pirrolidino alquilo, N-alquil piperazinil alquilo u oxopirrolidino alquilo, o R1 representa uno de los radicales representados por fórmulas (2), (3) y (4), o R1 representa además un radical -C(R11)(R12)-CO-R10; R2 representa un radical arilo carbocíclico o heterocíclico, opcionalmente sustituido, o R2 representa uno de los radicales de fórmulas (5) y (6); R3 representa un radical alquilo, adamantilo, arilo carbocíclico o heterocíclico opcionalmente sustituido, aralquilo carbocíclico o heterocíclico opcionalmente sustituido en el grupo arilo, o R3 representa uno de los radicales de fórmulas (7) y (8), o R3 representa también un radical -CO-R5; R4 representa H, alquilo, aralquilo carbocíclico o heterocíclico opcionalmente sustituido, en el radical arilo; o bien el radical de fórmula (9) representa un radical de la fórmula general (10) en la cual i representa un número entero de 1 a 3; R5 representa el radical N(R6)(R7); R6 representa un radical alquilo C1-16, cicloalquil alquilo, hidroxi alquilo, ariloxi alquilo, un radical aralquilo carbocíclico o heterocíclico opcionalmente sustituido en el grupo arilo, aralcoxi alquilo, aril hidroxi alquilo, alcoxi alquilo, alquil tioalquilo, alquenilo, alquinilo, ciclo hexenilo, ciclo hexenil alquilo, alquil tiohidroxi alquilo, ciano alquilo, N-acetamido alquilo, un radical bis-aril alquilo opcionalmente sustituido en los grupos arilo, un radical di-aril alquilo opcionalmente sustituido en los grupos arilo, un radical morfolino alquilo, pirrolidino alquilo, piperidino alquilo, N-alquil pirrolidinoalquilo, oxopirrolidino alquilo, tetrahidro furanil alquilo, N-bencilpirrolidino alquilo, N-alquil piperazinil alquilo, N-bencil piperazinil alquilo, N-bencilpiperidinil alquilo o N-alcoxi carbonil piperidinilo, o R6 representa un radical cicloalquilo(C3-8) cicloalquilo opcionalmente sustituido por un radical seleccionado del grupo que comprende al radical hidroxi y un radical alquilo, o R6 representa uno de los radicales de fórmulas (11), (12), (13) y (14); R7 representa H o un radical alquilo, hidroxialquilo, mono o diamino alquilo o aralquilo; o el radical -N(R6)(R7) representa el radical de fórmula (15) en la cual R8 representa H, alquilo, hidroxi alquilo, arilo carbocíclico o heterocíclico opcionalmente sustituido, aralquilo opcionalmente sustituido en el grupo arilo, alquenilo, alcoxi alquilo, cicloalquilo, cicloalquil alquilo, bis-aril alquilo, piperidinilo, pirrolidinilo, hidroxi, arilalquenilo, o R8 representa -X-(CH2)b-R9; R9 representa H o un radical alquilo, alcoxi, ariloxi, arilo carbocíclico o heterocíclico opcionalmente sustituido, morfolinilo, pirrolidinilo, alquilamino o N,N'-(alquil)(aril)amino; X representa CO, CO-NH ó SO2; Y representa CH ó N; a representa 1 ó 2, b representa un número entero de 0 a 6; o el radical N(R6)(R7) representa un radical de fórmula (16) en la cual Z representa CH, O ó S; c representa un número entero de 0 a 4, o el radical N(R6)(R7) representa uno de los radicales de fórmulas (17) a (32); R10 representa un radical amino (C2-7) alquil amino, ((amino alquil)aril) alquilamino, ((amino alquil) cicloalquil) alquil amino, piperazinilo, homopiperazinilo, o R10 representa el radical de fórmula (33); R11 representa H; y R12 representa H o un radical alquilo, un radical (C3-7)cicloalquilo, aralquilo carbocíclico o heterocíclico opcionalmente sustituido, propargilo, alilo, hidroxi alquilo, alquil tioalquilo, arilalquil alcoxi alquilo, arilalquiltio alcoxi alquilo; o una sal de un compuesto de la fórmula general (1). Estos compuestos son útiles, en particular en el tratamiento de los estados patológicos o enfermedades en las cuales intervienen uno o más de los receptores de la somatostatina, éstos estados incluyen en particular la acromegalia, los adenomas hipofiseales o los tumores gastroenteropancreáticos endocrinos que incluyen el Síndrome Carcinoide y las hemorragias gastrointestinales.
ARP000103722A 1999-07-22 2000-07-19 Derivados de 2-arilimino-2,3-dihidrotiazoles, procedimiento para su preparacion, y uso de los mismos para preparar medicamentos y composiciones farmaceuticas AR035321A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9909496A FR2796643B1 (fr) 1999-07-22 1999-07-22 Derives de 2-arylimino-2, 3-dihydrothiazoles, leurs procedes de preparation et leur utilisation therapeutique

Publications (1)

Publication Number Publication Date
AR035321A1 true AR035321A1 (es) 2004-05-12

Family

ID=9548380

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000103722A AR035321A1 (es) 1999-07-22 2000-07-19 Derivados de 2-arilimino-2,3-dihidrotiazoles, procedimiento para su preparacion, y uso de los mismos para preparar medicamentos y composiciones farmaceuticas

Country Status (19)

Country Link
US (1) US6727269B1 (es)
EP (1) EP1202980A1 (es)
JP (2) JP4063537B2 (es)
KR (1) KR100692352B1 (es)
CN (1) CN100443479C (es)
AR (1) AR035321A1 (es)
AU (1) AU782187B2 (es)
BR (1) BR0012647A (es)
CA (1) CA2382940C (es)
CZ (1) CZ302073B6 (es)
FR (1) FR2796643B1 (es)
HU (1) HUP0202425A3 (es)
IL (3) IL147582A0 (es)
MX (1) MXPA02000723A (es)
NO (1) NO322394B1 (es)
NZ (1) NZ516599A (es)
PL (1) PL353831A1 (es)
RU (1) RU2266287C2 (es)
WO (1) WO2001007424A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2819508B1 (fr) * 2001-01-12 2005-01-21 Sod Conseils Rech Applic Derives de 2-arylimino-2, 3-dihydorthiazoles, leurs procedes de preparation et leur utilisation therapeutiques
CN100369903C (zh) * 2000-06-30 2008-02-20 大日本住友制药株式会社 五元环化合物
DE10133665A1 (de) * 2001-07-11 2003-01-30 Boehringer Ingelheim Pharma Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung
AU2002359359A1 (en) 2001-12-28 2003-07-24 Somatocor Pharmaceuticals, Inc. Imidazolidin-2,4-dione derivatives as non-peptide somatostatin receptor ligands
US7067538B2 (en) 2002-08-09 2006-06-27 Warner-Lambert Company, Llc MCP-1 receptor antagonists and methods of use thereof
JP4896387B2 (ja) * 2003-09-30 2012-03-14 武田薬品工業株式会社 チアゾリン誘導体およびその用途
WO2005030740A1 (ja) * 2003-09-30 2005-04-07 Takeda Pharmaceutical Company Limited チアゾリン誘導体およびその用途
WO2005082844A1 (en) * 2004-02-27 2005-09-09 Oy Juvantia Pharma Ltd Treatment of diseases by using a somatostatin receptor agonist
WO2005082845A1 (en) * 2004-02-27 2005-09-09 Oy Juvantia Pharma Ltd Novel therapies with somatostatin receptor agonists
AU2012202459B2 (en) * 2004-03-15 2014-06-12 Janssen Pharmaceutica, N.V. Novel compounds as opioid receptor modulators
UA86053C2 (ru) 2004-03-15 2009-03-25 Янссен Фармацевтика Н.В. Соединения как модуляторы опиоидных рецепторов
US7910613B2 (en) * 2004-09-22 2011-03-22 H. Lundbeck A/S 2-acylaminothiazole derivatives
US7674912B2 (en) * 2005-04-25 2010-03-09 H. Lundbeck A/S Pro-drugs of N-thiazol-2-yl-benzamide derivatives
MX2008015214A (es) 2006-05-31 2008-12-12 Abbott Lab Compuestos como ligandos de receptor canabinoide y sus usos.
EP2038266A2 (en) * 2006-05-31 2009-03-25 Abbott Laboratories Compounds as cannabinoid receptor ligands and uses thereof
US8841334B2 (en) 2006-05-31 2014-09-23 Abbvie Inc. Compounds as cannabinoid receptor ligands and uses thereof
US7868038B2 (en) 2006-08-31 2011-01-11 Abbott Laboratories Compounds as cannabinoid receptor ligands
US7985768B2 (en) 2006-08-31 2011-07-26 Abbott Laboratories Compounds as cannabinoid receptor ligands
CN101765594A (zh) 2007-03-28 2010-06-30 雅培制药有限公司 作为大麻素受体配体的1,3-噻唑-2(3h)-亚基化合物
US7872033B2 (en) 2007-04-17 2011-01-18 Abbott Laboratories Compounds as cannabinoid receptor ligands
MX2009012374A (es) 2007-05-18 2009-12-01 Abbott Lab Compuestos novedosos como ligandos del receptor de canabinoides.
KR100863239B1 (ko) * 2007-05-23 2008-10-15 한국과학기술연구원 신규한 2-이미노-1,3-티아졸린계 화합물 및 이를 함유하는ｔ-형 칼슘 채널 저해제
US9193713B2 (en) 2007-10-12 2015-11-24 Abbvie Inc. Compounds as cannabinoid receptor ligands
CA2716857A1 (en) 2008-03-11 2009-09-17 Teodozyi Kolasa Novel compounds as cannabinoid receptor ligands
US8846730B2 (en) 2008-09-08 2014-09-30 Abbvie Inc. Compounds as cannabinoid receptor ligands
US8859596B2 (en) 2008-09-16 2014-10-14 Abbvie Inc. Compounds as cannabinoid receptor ligands
PA8854001A1 (es) 2008-12-16 2010-07-27 Abbott Lab Compuestos novedosos como ligandos de receptores de canabinoides
RU2562833C2 (ru) 2010-08-09 2015-09-10 НБ Хелс Лаборатори Ко. Лтд. Ингибитор казеинкиназы 1 дельта и казеинкиназы 1 е
KR20220034818A (ko) * 2019-07-10 2022-03-18 바이엘 악티엔게젤샤프트 2-(페닐이미노)-1,3-티아졸리딘-4-온의 제조 방법
EP3997076A1 (de) * 2019-07-10 2022-05-18 Bayer Aktiengesellschaft Verfahren zur herstellung von 2-(phenylimino)-1,3-thiazolidin-4-onen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3345257A (en) * 1962-01-19 1967-10-03 Ciba Ltd Method for combatting microorganisms
US3264316A (en) * 1963-09-18 1966-08-02 Res Lab Dr C Janssen N V Certain 2-acylimino-3-substitutedthiazoline-4 compounds
DE2926771A1 (de) * 1979-07-03 1981-01-15 Hoechst Ag Thiazolidinderivate und verfahren zu ihrer herstellung
DE3049460A1 (de) * 1980-12-30 1982-07-29 Hoechst Ag, 6000 Frankfurt "thiazolinderivate, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen
US5521145A (en) * 1994-04-04 1996-05-28 Sumitomo Chemical Company, Ltd. Iminothiazoline derivatives and herbicides containing them as active ingredients
JPH07324079A (ja) * 1994-04-04 1995-12-12 Sumitomo Chem Co Ltd イミノチアゾリン誘導体およびその用途
GB9705428D0 (en) * 1997-03-15 1997-04-30 Knoll Ag Therapeutic agents

Also Published As

Publication number Publication date
WO2001007424A1 (fr) 2001-02-01
AU782187B2 (en) 2005-07-07
IL185786A0 (en) 2008-01-06
CN100443479C (zh) 2008-12-17
MXPA02000723A (es) 2002-09-17
JP4063537B2 (ja) 2008-03-19
CZ2002187A3 (cs) 2002-06-12
NO20020314D0 (no) 2002-01-21
JP2003505453A (ja) 2003-02-12
AU7005300A (en) 2001-02-13
HUP0202425A3 (en) 2002-12-28
CZ302073B6 (cs) 2010-09-29
CN1362952A (zh) 2002-08-07
KR100692352B1 (ko) 2007-03-12
EP1202980A1 (fr) 2002-05-08
HUP0202425A2 (en) 2002-10-28
NZ516599A (en) 2004-01-30
PL353831A1 (en) 2003-12-01
RU2002104574A (ru) 2004-01-20
RU2266287C2 (ru) 2005-12-20
FR2796643B1 (fr) 2005-04-29
NO20020314L (no) 2002-03-06
NO322394B1 (no) 2006-10-02
HK1048314A1 (zh) 2003-03-28
US6727269B1 (en) 2004-04-27
BR0012647A (pt) 2002-04-09
JP2006257093A (ja) 2006-09-28
FR2796643A1 (fr) 2001-01-26
CA2382940A1 (fr) 2001-02-01
IL147582A0 (en) 2002-08-14
IL147582A (en) 2009-08-03
KR20020088405A (ko) 2002-11-27
CA2382940C (fr) 2010-08-17

Similar Documents

Publication Publication Date Title
AR035321A1 (es) Derivados de 2-arilimino-2,3-dihidrotiazoles, procedimiento para su preparacion, y uso de los mismos para preparar medicamentos y composiciones farmaceuticas
AR035068A1 (es) Compuestos de pirimidinona, composiciones farmaceuticas que los comprenden, uso de tales compuestos en la fabricacion de medicamentos y proceso para la preparacion de dichos compuestos
AR035349A1 (es) Compuestos de pirimidinona, composiciones farmaceuticas que los comprenden, uso de tales compuestos en la fabricacion de medicamentos y proceso para la preparacion de dichos compuestos
AR002012A1 (es) Un compuesto, una composicion farmaceutica que lo comprende, su uso, metodo de tratamiento terapeutico, metodo para la preparacion del compuesto.
UY25804A1 (es) Derivados de 4-aroilpiperidina que son antagonistas de los receptores ccr-3
AR060623A1 (es) Compuestos derivados de 2-azetidinona y un metodo de preparacion
PE20040155A1 (es) Derivados aminoinazoles, procedimiento de preparacion e intermedios de este procedimiento a titulo de medicamentos y composiciones farmaceuticas que los contienen
SE9904738D0 (sv) Novel compounds
MY135686A (en) Indole derivatives useful as histamine h3 antagonists
AR037429A1 (es) Derivados de piperidina antagonistas de la mch, composiciones farmaceuticas, un proceso para su elaboracion y el uso de dichos derivados, solos o en combinacion, para la fabricacion de un medicamento para tratamiento de la obesidad y de trastornos del snc
PE20030703A1 (es) Inhibidores de la 17b-hidroxiesteroide deshidrogenasa tipo 3
RU2007139453A (ru) Гетеробициклические ингибиторы вируса гепатита с (hcv)
AR038235A1 (es) Compuestos de espiropiperidina n-sustituidos como ligandos para el receptor orl-1
AR013370A1 (es) Derivados de 1,2,3,4-tetrahidronaftaleno sustituidos, formulacion farmaceutica que los comprende, su uso en la manufactura de un medicamento,proceso para su preparacion y compuestos intermediarios
BG100946A (bg) Нови аминокиселинни производни, метод за получаването им и фармацевтични състави съдържащи ги
EA200000616A1 (ru) Производные (бензодиоксана, бензофурана или бензопирана), обеспечивающие релаксацию мускулатуры дна желудка
AR015512A1 (es) Derivados ciclicos n-acilo amina, un procedimiento para su preparacion, un intermediario y una composicion farmaceutica
NI200600257A (es) Nuevos compuestos.
ATE326466T1 (de) Imidazopyridinderivate zur verwendung bei der behandlung von herpes-vireninfektion
AR006360A1 (es) Derivados de 1,2,3,4-tetrahidronaftaleno substituidos, uso de los mismos para la preparacion de medicamentos y procedimiento para su preparacion.
AR054482A1 (es) Derivados de azetidinona para el tratamiento de hiperlipidemias
MXPA05007494A (es) Nuevos compuestos.
AR035427A1 (es) Compuestos derivados de piperidina, su empleo, un procedimiento para prepararlos y medicamentos que los contienen
AR008296A1 (es) Compuestos derivados de tetrahidroquinolina, proceso para su preparacion, composiciones que los contienen y su uso en la preparacion de una composicion
AR037863A1 (es) Derivados de tetrahidrocarbazol como ligandos para receptores (gpcr) acoplados por medio de la proteina g

Legal Events

Date Code Title Description
FB Suspension of granting procedure